Study summary · research use only
Tesamorelin, a human growth hormone releasing factor analogue
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses tesamorelin, a synthetic human growth hormone releasing factor (GFR) analogue, in humans. The authors describe that clinical effectiveness alongside adverse effects of recombinant human growth hormone led to development of GFR analogues that may be better tolerated, and that tesamorelin has been developed as a potential treatment for conditions associated with relative GH deficiency, including HIV-related lipodystrophy. Relevant articles and abstracts were obtained from literature database searches. The review reports that a multicenter, randomized, placebo-controlled Phase III trial suggested tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a positive effect on reducing visceral fat, while noting that other potential indications appear less promising from current data. No specific numerical outcomes are provided in the abstract.
Abstract
The combination of clinical effectiveness with a variety of adverse side effects from the use of recombinant human growth hormone (rhGH) in therapy for growth hormone (GH)-deficient disorders has led to the development of human growth hormone releasing factor (GFR) analogues, which may be better tolerated. Tesamorelin, a synthetic GFR, has been developed as a potential treatment for a variety of conditions that may be associated with a relative deficiency of GH including HIV-related lipodystrophy. This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications. Relevant articles and abstracts were obtained from searches of the medical and chemical literature databases and the references from published articles. A multicenter, randomized, placebo-controlled, Phase III clinical trial suggested that tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat. Other potential indications for tesamorelin appear less promising from the current data.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.